ClinicalTrials.gg
CompletedNCT01607957RECOURSEUpdated Sep 19, 2024Results posted

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

A Phase 3 interventional study of TAS-102 and Placebo in Colorectal Cancer, sponsored by Taiho Oncology, Inc.. Completed at 115 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Colorectal Neoplasms · Otsuka Holdings Co., Ltd..

Enrollment
3rd of 13
800 · median 107
Started
2012
the only one that year
Phase 3
4 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 3, and was the 9th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.

Read the detailed description

This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Refractory, metastatic colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written
  2. Has adenocarcinoma of the colon or rectum
  3. Has failed at least 2 prior regimens of standard chemotherapies for colorectal cancer
  4. performance status of 0 or 1
  5. Is able to take medications orally
  6. Has adequate organ function (bone marrow, kidney and liver)
  7. Women of must have a negative pregnancy test and must agree to adequate if conception is possible. Males must agree to adequate birth control.

Exclusion criteria

Exclusion Criteria:

  1. Certain serious illnesses or medical condition(s)
  2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received agent, within the specified time frames prior to study drug administration
  3. Has received TAS-102
  4. Has unresolved toxicity of greater than or equal to Grade 2 attributed to any prior therapies
  5. Is a pregnant or lactating female
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (actual)

Study arms

  • Experimental
    TAS-102

    Drug: TAS-102

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTAS-102

    35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.

  • DrugPlacebo

    Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy.

    Time frame: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)

Secondary outcomes

  1. Progression-free Survival

    Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated.

    Time frame: Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)

  2. Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.

    Time frame: From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier

07

Results

Posted May 21, 2019

Participant flow

This was a multicenter study conducted in 101 study centers in 13 countries including the United States, Japan, Spain, Italy, Germany, Belgium, France, Australia, United Kingdom, Austria, Ireland, Sweden, and Czech Republic.

Participant flow — Overall Study
MilestoneTAS-102Placebo
Started534266
Treated533265
Completed16251
Not completed372215
Withdrew: Not treated11
Withdrew: Death367211
Withdrew: Lost to follow-up33
Withdrew: Participant refusal10

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy.

Time frame:
Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
Reported as:
Median · months
Overall Survival
monthsTAS-102Placebo
Overall Survival7.1 (6.5 to 7.8)5.3 (4.6 to 6.0)
Statistical analysis
  • TAS-102 vs Placebo · Stratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.68 · 95% CI 0.58 to 0.81
SecondaryProgression-free Survival

Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated.

Time frame:
Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
Reported as:
Median · months
Progression-free Survival
monthsTAS-102Placebo
Progression-free Survival2.0 (1.9 to 2.1)1.7 (1.7 to 1.8)
Statistical analysis
  • TAS-102 vs Placebo · Stratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.48 · 95% CI 0.41 to 0.57
SecondaryPercentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.

Time frame:
From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths
percentage of participantsTAS-102Placebo
Any adverse event (AE)98.393.2
Any treatment-related AE85.754.7
Any ≥Grade 3 AE69.451.7
Any treatment-related ≥Grade 3 AE49.09.8
Any serious AE (SAE)29.633.6
Any AE resulting in discontinuation10.313.6
Any AE with outcome of death3.211.3

Adverse events

Collected over From the time of signing the informed consent form until the period of participant follow up (30 days following the administration of last dose of study medication or until initiation of new anti-tumor therapy, whichever was earlier, up to 85 weeks approximately (duration of study)).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAS-10217/533 (3.2%)158/533 (29.6%)506/533 (94.9%)
Placebo30/265 (11.3%)89/265 (33.6%)227/265 (85.7%)
Most frequent serious events
Showing 10 of 154
Most frequent serious events
EventTAS-102Placebo
General physical health deteriorationGeneral disorders15/53311/265
Febrile neutropeniaBlood and lymphatic system disorders14/5330/265
Hepatic failureHepatobiliary disorders3/5336/265
DyspnoeaRespiratory, thoracic and mediastinal disorders3/5336/265
Abdominal painGastrointestinal disorders8/5335/265
IleusGastrointestinal disorders3/5335/265
Decreased appetiteMetabolism and nutrition disorders3/5335/265
AnaemiaBlood and lymphatic system disorders10/5330/265
VomitingGastrointestinal disorders7/5330/265
AscitesGastrointestinal disorders3/5333/265
Most frequent other events
Showing 10 of 35
Most frequent other events
EventTAS-102Placebo
NauseaGastrointestinal disorders256/53363/265
Decreased appetiteMetabolism and nutrition disorders206/53376/265
AnaemiaBlood and lymphatic system disorders205/53322/265
FatigueGeneral disorders185/53360/265
DiarrhoeaGastrointestinal disorders167/53333/265
NeutropeniaBlood and lymphatic system disorders152/5330/265
Neutrophil count decreasedInvestigations148/5331/265
White blood cell count decreasedInvestigations146/5331/265
VomitingGastrointestinal disorders142/53338/265
AstheniaGeneral disorders96/53329/265

Baseline characteristics

Analysis was performed in Intent-to-Treat (ITT) population which included all randomized participants.

Age, Categorical
Age, Categorical(Participants)TAS-102PlaceboTotal
<=18 years000
Between 18 and 65 years300148448
>=65 years234118352
Age, Continuous
Age, Continuous(years)TAS-102PlaceboTotal
Mean61.5 ± 10.2161.5 ± 10.5161.5 ± 10.30
Sex: Female, Male
Sex: Female, Male(Participants)TAS-102PlaceboTotal
Female208101309
Male326165491
08

Study locations

115 sites
  • Arizona Center for Cancer Care
    Glendale, Arizona 85306, United States
  • California Cancer Associates for Research and Excellence
    Fresno, California 93720, United States
  • Ronald H. Yanagihara, MD
    Gilroy, California 95020, United States
  • LAC and USC Medical Center
    Los Angeles, California 90033, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Pacific Hematology Oncology Associates
    San Francisco, California 94115, United States
  • San Jose Medical Group
    San Jose, California 95124, United States
  • Coastal Integrative Cancer Care
    San Luis Obispo, California 93401, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • MD Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Illinois Cancer Care, P.C.
    Peoria, Illinois 61615, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Mary Bird Perkins Cancer Center
    Baton Rouge, Louisiana 70809, United States
  • Ochsner Clinic Fndtn
    New Orleans, Louisiana 70121-2429, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • St. Joseph Mercy Hospital
    Ann Arbor, Michigan 48106, United States
  • Jefferson City Medical Group
    Jefferson City, Missouri 65109-6023, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Hickman Cancer Center at Flower Hospital
    Sylvania, Ohio 43560, United States
  • Hematology/Oncology Associates of Fredericksburg
    Fredericksburg, Virginia 22408, United States
  • Royal North Shore Hospital
    Sydney, New South Wales 2065, Australia
  • The Queen Elisabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Sir Charles Gairdner Hospital
    Perth, Western Australia 6009, Australia
  • Krankenhaus der Barmherzigen Schwestern Linz
    Linz, 4010, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Wels, 4600, Austria
  • Universitaet Wien
    Wien, 1090, Austria
  • Universitaetsklinik fur Innere Medizin
    Wien, 1090, Austria
  • Wilhelminenspital Wien
    Wien, 1160, Austria
  • Cliniques Universitaires UCL St. Luc
    Brussels, 1200, Belgium
  • Erasme University Hospital-ULB-Brussels
    Brussels, B-1070, Belgium
  • Grand Hospital de Charleroi
    Charleroi, 6000, Belgium
  • Antwerp University Hospital
    Edegem, 2650, Belgium
  • University Hospital Gent
    Edegem, 2650, Belgium
  • University Hospital Gent
    Gent, 9000, Belgium
  • Leuven University Hospital - Campus Gasthuiseberg
    Leuven, 3000, Belgium
  • University Hospital Gasthuisberg
    Leuven, 3000, Belgium
  • Klinika onkologie a radioteraie, Facultni nemocnice Hradec Kralove
    Hradec Kralove, 50005, Czechia
  • Institute of Oncology and Rehabilitation Ples
    Nova Ves pod Plesi, 26204, Czechia
  • CHU de Becançon
    Besancon, 25030, France
  • University Hospital of Bordeaux
    Bordeaux, 33075, France
  • Centre Oscar Lambret
    Lille, 59020, France
  • CRLC Val d'Aurelle
    Montpellier, 34298, France
  • Hopital Saint Antoine
    Paris cedex 12, 75571, France
  • Centre Eugene Marquis
    Rennes cedex, 35042, France
  • Onkologische Schwerpunktpraxis Kurfuerstendamm
    Berlin, 10707, Germany
  • Praxiskooperation Bonn-Euskirchen-Rheinbach
    Bonn, 53123, Germany
  • Universitatsklinikum Carl Gustav Carus - Dresden
    Dresden, 1307, Germany
  • Medizinische Klinik am Krankenhaus Nordwest GmbH
    Frankfurt, 60488, Germany
  • Uniklinik der Martin-Luther-Universitaet Halle-Wittenberg
    Halle (Saale), 6120, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Uniklinik Koeln
    Koeln, 50937, Germany
  • Johannes Gutenberg Universität Mainz
    Mainz, 55131, Germany
  • Interdisziplinaeres Tumorzentrum Mannheim
    Mannheim, 68167, Germany
  • Staedtisches Klinikum Muenchen / Klinikum Neuperlach
    Muenchen, 81737, Germany
  • Klinikum der Universität München - Großhadern
    München, 81377, Germany
  • Klinikum Oldenburg gGmbH
    Oldenburg, 26133, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89081, Germany
  • Bon Secours Hospital
    Cork, Ireland
  • Adelaide and Meath Hospital
    Dublin, 24, Ireland
  • St. Vincent's University Hospital
    Dublin, 4, Ireland
  • Fondazione Poliambulanza
    Brescia, Lombardy 25124, Italy
  • Universita Delgi Studi de Genova (UNIGE)- Azienda Ospedaliera. Universitaria "San Martino" (Ospedale San Martino)
    Genova, 16132, Italy
  • Fondazione IRCCS Instituto Nazionale dei Tumori Milano
    Milano, 20133, Italy
  • A.O. Ospedale Niguarda Ca' Granda
    Milan, 20162, Italy
  • A.O. R.N. "A.Cardarelli"
    Naples, 80131, Italy
  • Seconda Universita degli Studi de Napoli
    Napoli, 80131, Italy
  • AOU San Luidi di Orbassano
    Orbassano, 1010043, Italy
  • Azienda Ospedaliero
    Pisa, 6756126, Italy
  • Arcispidale S Maria Nuova
    Reggio Emilia, 42123, Italy
  • Ospedale di Rimini
    Rimini, 47923, Italy
  • Ospedale di Sondrio
    Sondrio, 23100, Italy
  • Aichi Cancer Center Hospital
    Nagoya, Aichi 4648681, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-0882, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 2778577, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 7910280, Japan
  • KKR Sapporo Medical Center TONAN-Hospital
    Sapporo, Hokkaido 0600001, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 0608648, Japan
  • Kobe City Medical Center General Hospital
    Kobe, Hyogo 6500047, Japan
  • Tsukuba University Hospital
    Tsukuba, Ibaraki 3058576, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa 2418515, Japan
  • Osaka Medical College Hospital
    Takatsuki, Osaka 5698686, Japan
  • Saitama Cancer Center
    Kita-adachi-gun, Saitama 3620806, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 4118777, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 3290498, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 1040045, Japan
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Koto-ku, Tokyo 1358550, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 1608582, Japan
  • Chiba Cancer Center
    Chiba, 2608717, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 8111395, Japan
  • Kumamoto University Hospital
    Kumamoto, 8608556, Japan
  • Osaka Medical Center for Cancer and Cardiovascular Diseases
    Osaka, 5378511, Japan
  • Tokushima University Hospital
    Tokushima, 7708503, Japan
  • Hospital Universitario Vall d'Hebrón
    Barcelona, 8035, Spain
  • Hospital Arnau de Vilanova
    Lleida, 25198, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain

Showing the first 100 of 115 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argiles G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 Jan;31(1):88-95. doi: 10.1016/j.annonc.2019.10.005. PubMed 31912801 ↗
  • Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Gravalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21. PubMed 29274618 ↗
  • Longo-Munoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limon ML, Garcia-Carbonero R. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clin Transl Oncol. 2017 Feb;19(2):227-235. doi: 10.1007/s12094-016-1528-7. Epub 2016 Jul 21. PubMed 27443414 ↗
  • Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. PubMed 25970050 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jan 2014, 19 months.

Results were first posted in May 2019, 5 years 3 months after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 19 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2012
First posted
May 30, 2012
StartActual
Jun 17, 2012
Primary completionActual
Jan 31, 2014
CompletionActual
May 23, 2016
Results first posted
May 21, 2019
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01607957
Responsible party
Sponsor
First posted
May 30, 2012
Start date
Jun 17, 2012
Primary completion
Jan 31, 2014
Completion
May 23, 2016
Results posted
May 21, 2019
Last update
Sep 19, 2024

Study contacts

From - Boston, MA
principal investigator · Dana-Farber Cancer Institute
From - Leuven, Belgium
principal investigator · University Hospital, Gasthuisberg
From - Kashiwa, Chiba Japan
principal investigator · National Cancer Center Hospital East

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion